secwatch.observer — SEC 8-K summary
======================================

Issuer:     MADRIGAL PHARMACEUTICALS, INC. (MDGL)
CIK:        0001157601
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001628280-25-037596
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Madrigal Q2 2025: Rezdiffra sales $212.8M, 23k patients; new patent to 2045; $500M credit
--------------------------------------------------------------------------------

- Q2 2025 Rezdiffra net sales $212.8M (vs $14.6M prior year); >23,000 patients on therapy as of June 30, 2025.
- New U.S. patent (No. 12,377,104) covers Rezdiffra weight-threshold dosing; expires Feb 4, 2045 (previously Sept 30, 2044).
- Licensed global rights to oral GLP-1 candidate SYH2086 from CSPC Pharma; enters clinic H1 2026 for MASH combination.
- Secured $500M senior secured credit facility with Blue Owl: $350M initial term loan, $150M delayed draw, plus up to $250M incremental.
- Positive CHMP opinion for Rezdiffra in Europe; EC decision expected Aug 2025; would be first MASH therapy in EU.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157601/000162828025037596/0001628280-25-037596-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157601/000162828025037596/mdgl-20250805.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-037596

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer